์๋ฅด๊ณ ์นผ์ํ๋กค (๋นํ๋ฏผ D2)
**์๋ฅด๊ณ ์นผ์ํ๋กค(๋นํ๋ฏผ D2)**์ ์ง์ฉ์ฑ ๋นํ๋ฏผ์ด์ **๋นํ๋ฏผ D ์ ์ฌ์ฒด**๋ก, ์์ํ์์ ์ฃผ๋ก ๋ถ๊ฐ์์ ๊ธฐ๋ฅ ์ ํ์ฆ๊ณผ ๊ด๋ จ๋ ์ ์นผ์ํ์ฆ์ ๊ด๋ฆฌํ๋ ๋ฐ ์ฌ์ฉ๋ฉ๋๋คใ * **๋น์ฉ ํจ์จ์ฑ**: ์นผ์ํธ๋ฆฌ์ฌ์ด๋ ๋ํ๋๋กํํค์คํ ๋กค(DHT)์ ์ ๋ ดํ ๋์์ผ๋ก ์์ฃผ ์ ํ๋ฉ๋๋ค. * **์ง์ฐ๋ ํจ๊ณผ ๋ฐํ**: ๊ฐ ๋ฐ ์ ์ฅ์ ํจ์ ํ์ฑํ๊ฐ ํ์ํ๊ธฐ ๋๋ฌธ์ ํ์ฑ ๋์ฌ์ฒด์ ๋นํด ํ์ฒญ ์นผ์์ ์ต๋ ํจ๊ณผ๋ฅผ ๋ํ๋ด๋ ๋ฐ ๋ ์ค๋ ์๊ฐ(5~21์ผ)์ด ๊ฑธ๋ฆฝ๋๋ค. * **์ง์์ ์ธ ๋ ์ฑ**: ์ง์ฉ์ฑ์ด ๋์ ์ง๋ฐฉ์ ์ ์ฅ๋ฉ๋๋ค. ๊ณ ์นผ์ํ์ฆ์ด ๋ฐ์ํ๋ฉด ์ฝ๋ฌผ ํฌ์ฌ๋ฅผ ์ค๋จํ๋๋ผ๋ ๋ ์ฑ ํจ๊ณผ๊ฐ ์ต๋ 18์ฃผ๊น์ง ์ง์๋ ์ ์์ต๋๋ค. > **์์ ์์ **: ๊ณ ์์ด๋ ์ฝ๋ ์นผ์ํ๋กค(๋นํ๋ฏผ D3)์ ๋นํด ์๋ฅด๊ณ ์นผ์ํ๋กค์ 25-ํ๋๋ก์คํ ํํ๋ก ํจ์จ์ ์ผ๋ก ๋ณํํ์ง ๋ชปํฉ๋๋ค. ๋ฐ๋ผ์ ๊ณ ์์ด ํ์์ ์ ์นผ์ํ์ฆ ๊ด๋ฆฌ์๋ ์ผ๋ฐ์ ์ผ๋ก ์นผ์ํธ๋ฆฌ์ฌ์ด ์ ํธ๋ฉ๋๋ค.
์์ฉ ๊ธฐ์ : Ergocalciferol is an inactive prodrug that requires a two-step enzymatic activation process to regulate calcium homeostasis: 1. Ergocalciferol โ **hepatic 25-hydroxylase** โ 25-hydroxyvitamin D2 (calcidiol, partially active). 2. 25-hydroxyvitamin D2 โ **renal 1-alpha-hydroxylase** โ 1,25-dihydroxyvitamin D2 (fully active calcitriol equivalent). The active metabolite binds to intracellular **Vitamin D Receptors (VDR)**, acting as a hormone alongside parathyroid hormone (PTH) and calcitonin to: * Enhance intestinal absorption of calcium and phosphate. * Promote renal tubular reabsorption of calcium. * Increase the rate of accretion and osteoclastic resorption of minerals in bone, mobilizing calcium into the extracellular fluid.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Maintenance therapy of parathyroid failure after using parenteral calcium to control hypocalcemic tetany ยท Initially 4000-6000 Units/kg PO once daily. Maintenance doses usually range from 1000-2000 Units/kg PO once daily to once weekly. ยท PO ยท once daily to once weekly ยท Lifelong ยท Patient should be hospitalized initially. Adjust dosage to maintain serum calcium concentrations between 8-9.5 mg/dL. Goal is to prevent hypocalcemic tetany, but not induce hypercalcemia.
- Maintenance therapy of parathyroid failure after using parenteral calcium to control hypocalcemic tetany ยท Initially 4000-6000 Units/kg PO once daily. Maintenance doses usually range from 1000-2000 Units/kg PO once daily to once weekly. ยท PO ยท once daily to once weekly ยท Lifelong ยท Patient should be hospitalized initially. Adjust dosage to maintain serum calcium concentrations between 8-9.5 mg/dL. Goal is to prevent hypocalcemic tetany, but not induce hypercalcemia.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Hypercalcemia
- Vitamin D toxicity
- Malabsorption syndrome
- Abnormal sensitivity to the effects of vitamin D
์ด์๋ฐ์
- Hypercalcemia
- Hyperphosphatemia
- Nephrocalcinosis
- Soft tissue mineralization
์ฝ๋ฌผ ์ํธ์์ฉ
- Corticosteroids ยท Can reduce the effects of vitamin D analogs by decreasing calcium absorption and increasing renal excretion.
- Digoxin ยท Patients are highly sensitive to the arrhythmogenic effects of hypercalcemia; intensified monitoring is required.
- Verapamil ยท Patients are sensitive to the effects of hypercalcemia; intensified monitoring is required.
- Mineral Oil ยท May reduce the amount of orally administered ergocalciferol absorbed from the GI tract.
- Thiazide Diuretics ยท May cause hypercalcemia when given in conjunction with Vitamin D analogs due to decreased renal calcium excretion.
๋ชจ๋ํฐ๋ง
- Serum calcium concentrations (weekly initially, then monthly for 6 months, then every 2-3 months)
- Serum phosphorus concentrations
- Renal function parameters (BUN, Creatinine)
- Clinical signs of hypercalcemia (PU/PD, lethargy, anorexia, vomiting)
๊ณผ์ฉ๋
### Acute Toxicity * The toxic acute oral dose of ergocalciferol in dogs is reported as **4 mg/kg (160,000 Units/kg)**. * **Decontamination**: Acute ingestions should be managed using established protocols for removal or prevention of GI absorption. Orally administered **mineral oil** may reduce absorption and enhance fecal elimination. ### Chronic Overdosage (Hypercalcemia) * **Immediate Action**: Temporarily discontinue ergocalciferol and any exogenous calcium therapy. * **Medical Management**: If hypercalcemia is severe, administer **0.9% normal saline** (calcium-free IV fluids), **furosemide** (to promote calciuresis), and **corticosteroids** (to decrease GI absorption and increase renal excretion of calcium). Urine acidification may also be employed. * **Prolonged Effect**: Because of the long duration of action (potentially up to 18 weeks), hypercalcemia may persist for weeks to months. Restart therapy at a reduced dosage only when calcium serum levels return to the normal range.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.